Applied Imaging Wins FDA Approval for Cancer Cell Detection System
SANTA CLARA, Calif., Sept. 8 -- The US Food and Drug Administration has approved Applied Imaging Corp.'s MDS system to help pathologists locate micrometastatic cells in bone marrow specimens that are associated with the spread of a rare form of cancer.
This rapid FDA clearance of the first clinical application for the MDS represents the achievement of a significant milestone for the company, said Jack Goldstein, chairman and CEO of Applied Imaging. Our clinical data showed that pathologists using the MDS detected 46 percent more patients with metastatic cells than they detected by unaided microscopic examination. This substantial improvement will allow us to market the MDS system to thousands of cancer centers worldwide, presenting us with a dramatically expanded opportunity for the company's products.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024